CFH

Gemini Therapeutics Provides Corporate Update

Retrieved on: 
Monday, February 28, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Workforce, Risk, Board of directors, File, Board, Twitter, U.S. Securities and Exchange Commission, Anetoderma, Annual report, COVID-19, Therapy, Company, Social media, CFH, AMD, LinkedIn, Securities Act of 1933, Disclosure, Nasdaq, Forward-looking statement, Patient, CEO, SEC, Pharmaceutical industry, Management

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.
  • As part of its corporate restructuring, Gemini intends to reduce its workforce by 24 employees, approximately 80 percent, by the end of the second quarter of 2022 with remaining employees focused on GEM307s IND-enabling tasks.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.

Gemini Therapeutics Provides GEM103 Program Update

Retrieved on: 
Monday, January 10, 2022
Biotechnology, Health, General Health, Seniors, Pharmaceutical, Optical, Research, Genetics, Consumer, Science, Clinical Trials, Securities Act of 1933, SEC, Safety, Risk, Social media, AMD, LinkedIn, Pharmacokinetics, Patient, Factor, Time-invariant system, Forward-looking statement, Annual report, CFH, Therapy, Intravitreal injection, U.S. Securities and Exchange Commission, Biomarker, Company, File, Nasdaq, Boat, COVID-19, Twitter, Complement, Anetoderma, Pharmaceutical industry, Risk management

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103s clinical development program.

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103s clinical development program.
  • Interim analysis showed that intravitreal GEM103 plus aflibercept was generally well-tolerated, and the safety profile was generally consistent with the sham plus aflibercept arm.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.

United Kingdom EMR Market Report 2021-2026 - Growing Demand for an Integrated Health Care System - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 1, 2021
Health, Practice Management, Patient, WHO, CFH, Government, Health, Coronavirus, EMR, Industry, United Kingdom, NHS, Growth, COVID-19, Department of Health and Social Care, Efficiency, Animal, Health insurance, Pharmaceutical industry

The rapid increase in digitalization in the health care industry of UK has significantly contributed to the increase in the EMR market.

Key Points: 
  • The rapid increase in digitalization in the health care industry of UK has significantly contributed to the increase in the EMR market.
  • The growing demand for an integrated health care system is expected to drive the demand for this market in the forecast period.
  • The growing need for an integrated healthcare system has been a major key driver in the UK EMR market.
  • Also, with rising health consciousness among the netizens of UK, the EMR system is widely accepted in UK.

Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 15, 2021
Health, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Population, American Academy of Ophthalmology, Retinal pigment epithelium, Therapy, Anetoderma, COVID-19, Factor, Indiana University School of Medicine, Drug Quality and Security Act, Smoking, Risk, PK, Safety, Biomarker, Tissue, International Conference on Emerging Infectious Diseases, Western world, Social media, Securities Act of 1933, Forward-looking statement, RPE, Severe cognitive impairment, Clinical trial, Conference, Research, Geographic atrophy, Summit, Poster, Patient, FDA, Boat, Ageing, Choroid, Eye, Disease, Night vision, Twitter, American Academy, U.S. Securities and Exchange Commission, SEC, Pharmacokinetics, Retina, CNV, Reading, AAO, Vance DeGeneres, Annual report, AMD, CFH, File, Company, LinkedIn, Intravitreal injection, Complement, Nasdaq, Pharmaceutical industry, Medical device, Cryptocurrency, the Phase 2a ReGAtta Study, GEM103, Dry Age-Related Macular Degeneration (AMD), Gemini Therapeutics, THE PHASE 2A REGATTA STUDY, GEM103, DRY AGE-RELATED MACULAR DEGENERATION (AMD), GEMINI THERAPEUTICS

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD) today reported its financial results for the third quarter ended September 30, 2021 and provided a business update.

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD) today reported its financial results for the third quarter ended September 30, 2021 and provided a business update.
  • In October 2021, Gemini announced a corporate restructuring including several executive officer transitions to prioritize assets and focus on initiating and executing GEM103s resource-intensive pivotal trial in GA.
  • At September 30, 2021, Gemini held $150.1 million in cash, $6.7 million of principal outstanding debt and 43.1 million shares outstanding.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

Gemini Therapeutics Announces Poster Presentation at AAO 2021

Retrieved on: 
Friday, November 12, 2021
Health, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Safety, Indiana University School of Medicine, Therapy, Plasma, Investor, CNV, Recurrence, Ernest, Inflammation, Autoimmune disease, Anetoderma, COVID-19, Social media, AAO, Securities Act of 1933, Forward-looking statement, Annual report, AMD, CFH, File, Choroidal neovascularization, Twitter, American Academy, GEM, LinkedIn, U.S. Securities and Exchange Commission, History, SEC, Nasdaq, Poster, Patient, Risk, Boat, Pharmaceutical industry, Vaccine, Risk management

Details of the virtual poster at the AAO meeting include:

Key Points: 
  • Details of the virtual poster at the AAO meeting include:
    This poster (PO329) features newly available data that updates the May 2021 initial data from the Companys ongoing ReGAtta Phase 2a study of GEM103.
  • Information on Gemini Therapeutics, including GEM103 and initial ReGAtta data, and the e-poster presented at AAO 2021, can be found on Gemini Therapeutics website under the Investors & Media section: Events and Presentations .
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.

Gemini Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, November 11, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Anetoderma, Social media, Securities Act of 1933, AMD, CFH, File, Twitter, Company, LinkedIn, U.S. Securities and Exchange Commission, Nasdaq, Patient, Risk, Pharmaceutical industry

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November:

Key Points: 
  • Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November:
    The presentation will be available on-demand starting at 8 AM GMT on Thursday, November 18, 2021.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.
  • As a result, Gemini encourages investors, the media, and others interested in Gemini to review the information that is posted on these channels, including the investor relations website, on a regular basis.

Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit

Retrieved on: 
Tuesday, October 19, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Anetoderma, Risk, Twitter, COVID-19, Complement, AMD, U.S. Securities and Exchange Commission, Factor, CFH, LinkedIn, Social media, Annual report, Securities Act of 1933, Nasdaq, File, Therapy, Patient, Forward-looking statement, SEC, Safety, Pharmaceutical industry

Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

Key Points: 
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy.
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.
  • The information that Gemini posts on these channels and websites could be deemed to be material information.

Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, October 14, 2021
Biotechnology, Pharmaceutical, Optical, Health, Risk, Nasdaq, Employment, Patient, Therapy, Gemini, CFH, AMD, Anetoderma, Pharmaceutical industry

In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Geminis Compensation Committee and made as a material inducement to each employees entry into employment with Gemini.

Key Points: 
  • In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Geminis Compensation Committee and made as a material inducement to each employees entry into employment with Gemini.
  • The agreements covering these option awards are consistent with Geminis standard stock option inducement award agreement.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.

Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy

Retrieved on: 
Tuesday, October 5, 2021
Health, Genetics, Other Health, General Health, Clinical Trials, Research, Science, People, U.S. Securities and Exchange Commission, Social media, Therapy, Geographic atrophy, Securities Act of 1933, Partnership, Sustainability Accounting Standards Board, Pharmacokinetics, Annual report, Boat, AMD, Patient, CFH, SEC, LinkedIn, Biomarker, Complement factor I, Board, Controller, CFI, Twitter, Company, Complement, Risk, Praecilia gens, COVID-19, Research, Forward-looking statement, Safety, File, Nasdaq, Anetoderma, GA, Factor, Pharmaceutical industry, Public relations, Management

Therefore, we are shifting Geminis focus from a research and development organization to exclusively become a development-stage company.

Key Points: 
  • Therefore, we are shifting Geminis focus from a research and development organization to exclusively become a development-stage company.
  • Gemini will concentrate its resources to advance GEM103 for the treatment of genetically defined age-related macular degeneration (AMD).
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.

James & James Launches as the First Craft CBD Seltzer Made With Single-Sourced and Hand-Harvested Full Spectrum Hemp Flower Extract

Retrieved on: 
Tuesday, September 14, 2021
Wax, Wind, Glass, USDA, Fats, THC, Genetics, Terpene, Chemistry (relationship), Drink, New, James James, CFH, Cancer, Light, Brain, Hemp, GLOBE, Mark (given name), Cannabinoid, Bottled water, Textile

Longmont, Colo., Sept. 14, 2021 (GLOBE NEWSWIRE) -- New CBD seltzer brand James & James launches as the first craft sparkling beverage made with full spectrum, hemp flower-derived CBD extract sourced from in-house hemp.

Key Points: 
  • Longmont, Colo., Sept. 14, 2021 (GLOBE NEWSWIRE) -- New CBD seltzer brand James & James launches as the first craft sparkling beverage made with full spectrum, hemp flower-derived CBD extract sourced from in-house hemp.
  • Each 12 oz glass bottle of James & James features 25mg of CBD sourced from its parent company CFH Ltd.s Colorado farm.
  • As the latest product by CFH, Ltd. , a vertically integrated, Colorado-based CBD bioscience company and USDA Certified Organic hemp farm founded in 2014, James & James only uses hemp sourced from hand-harvested flower.
  • All CFH products, including James & James, are made from industrial hemp and contain less than 0.3 percent THC.